Skip to Content

Zanamivir Disease Interactions

There is 1 disease interaction with zanamivir:


Zanamivir (Includes zanamivir) ↔ asthma/COPD

Severe Potential Hazard, Moderate plausibility. Applies to: Asthma, Chronic Obstructive Pulmonary Disease

Serious respiratory adverse events, including bronchospasm and/or decline in lung function, have been reported during clinical trials and postmarketing use of zanamivir. The manufacturer does not generally recommend its use in patients with underlying airways disease such as asthma or chronic obstructive pulmonary disease. However, if it is prescribed, these patients should have a fast-acting inhaled bronchodilator readily available whenever zanamivir is administered. The drug should be stopped and the physician notified in case of worsening respiratory symptoms. Patients scheduled to use an inhaled bronchodilator at the same time as the zanamivir dose should use their bronchodilator before administering zanamivir.


  1. "Product Information. Relenza (zanamivir)" Glaxo Wellcome, Research Triangle Pk, NC.

Zanamivir drug interactions

There are 3 drug interactions with zanamivir

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.